Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255

Benzinga Newsdesk www.benzinga.com Neutral 49.3%

Neg 0% Neu 49.3% Pos 0%

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.